NCT06242418 - CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Colon Cancer

Interventions

DRUG

FOLFOXIRI

Eight cycles of FOLFOXIRI: Oxaliplatin 85mg/m2 ivgtt over 2 hours on day 1, Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1, Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1, 5-Fluorouracil 2400mg/m2 civ48h; Each cycle lasts for 2 weeks.

DRUG

XELOX

Five cycles of XELOX: Oxaliplatin 130mg/m2 on day 1, Capecitabine 1000mg/m2 bid from day 1 to day 14; Each cycle lasts for 3 weeks.

Trial Locations (9)

610041

RECRUITING

West China Hospital of Sichuan University, Chengde

Unknown

RECRUITING

The Affiliated Hospital of Guizhou Medical University, Guiyang

RECRUITING

People's Hospital of Sichuan Province, Chengdu

RECRUITING

Shang Jin Hospital of West China Hospital, Sichuan University, Chengdu

RECRUITING

Sichuan Cancer Hospital, Chengdu

RECRUITING

The Third People's Hospital of Chengdu, Chengdu

RECRUITING

West China Tianfu Hospital, Sichuan University, Chengdu

RECRUITING

First Affiliated Hospital of Kunming Medical University, Kunming

RECRUITING

Yunnan Cancer Hospital, Kunming